function confirmModerate(url,num,pid){ url = url + '?Comments[do]=mod&Comments[pid]=' + pid + '&Comments[id]=' + num + '#Comments_' + num; if (confirm('Do you want to report this comment as inappropriate?')) location.href=url; return 0; } function validate_form(frm) { var value = ''; var errFlag = new Array(); _qfMsg = ''; value = frm.elements['Comments[name]'].value; if (value == '' && !errFlag['name']) { errFlag['name'] = true; _qfMsg = _qfMsg + '\n - Please enter your name'; } value = frm.elements['Comments[captcha]'].value; if (value == '' && !errFlag['captcha']) { errFlag['captcha'] = true; _qfMsg = _qfMsg + '\n - Please enter Security Code'; } value = frm.elements['Comments[mail]'].value; if (value == '' && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - Please enter your e-mail'; } var regex = /^((\"[^\"\f\n\r\t\v\b]+\")|([\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+(\.[\w\!\#\$\%\&'\*\+\-\~\/\^\`\|\{\}]+)*))@((\[(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))\])|(((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9]))\.((25[0-5])|(2[0-4][0-9])|([0-1]?[0-9]?[0-9])))|((([A-Za-z0-9\-])+\.)+[A-Za-z\-]+))$/; if (value != '' &&!regex.test(value) && !errFlag['mail']) { errFlag['mail'] = true; _qfMsg = _qfMsg + '\n - E-mail address format is invalid'; } value = frm.elements['Comments[text]'].value; if (value == '' && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Please enter your comment'; } if (value.length<50 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too short (50 characters min.)'; } if (value.length>4000 && !errFlag['text']) { errFlag['text'] = true; _qfMsg = _qfMsg + '\n - Comment is too long (4000 characters max)'; } if (_qfMsg != '') { _qfMsg = 'Invalid information entered:' + _qfMsg + '\nPlease correct these fields.'; alert(_qfMsg); return false; } return true; } //]]>

Trying to deliver in the future

Article Abstract:

Shire Pharmaceuticals is acquiring Pharmavene, a biotechnology concern, for 105 million pounds sterling. The deal involves 15 million pounds of an initial 55 million pounds to be paid in cash and the remainder in shares. Drug delivery is an expanding market and Pharmavene offers a range of drug delivery technologies. Pharmavene also brings 11 possible drugs to Shire Pharmaceuticals. An epilepsy drug has been registered in the US. The deal also involves risks for Shire.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1997

Biochemistry, Research and Development in the Physical, Engineering, and Life Sciences, Mergers, acquisitions and divestments, Shire Pharmaceuticals Group PLC, Pharmavene Inc.

User Contributions:

Comment about this article or add new information about this topic:

Sygen

Article Abstract:

Pig breeder Sygen International is enjoying buoyant growth and its shares are tipped as a good buy. Sygen provides farmers with disease-resistant pigs, and now wants to move into the higher-growth poultry and fish sectors.

Publisher: FT Business
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 2001

Hogs, Hog and Pig Farming, Securities, Swine, Animal breeders, Sygen International

User Contributions:

Comment about this article or add new information about this topic:

Subjects list: Biotechnology industry, Biotechnology industries

Similar abstracts:

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.